Clinical trial · Interventional
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors
NCT01204996CI-TRIAL-00007021completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CNTO888 + docetaxel | Drug | — | UNRESOLVED |
| CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection | Drug | — | UNRESOLVED |
| CNTO888 + gemcitabine | Drug | — | UNRESOLVED |
| CNTO888 + Paclitaxel and carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- 1
- description
- CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
- interventionNames
- Drug: CNTO888 + docetaxel
- type
- EXPERIMENTAL
- label
- 2
- description
- CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
- interventionNames
- Drug: CNTO888 + gemcitabine
- type
- EXPERIMENTAL
- label
- 3
- description
- CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Documentation of an advanced solid tumor * No more than 2 previous anticancer therapies * good performance status * adequate bone marrow, liver, and renal function / adequate blood test values * willing to use birth control measures Exclusion Criteria: * No residual toxicities resulting from previous therapy * no known allergies, hypersensitivity, or intolerance to antibodies or chemotherapies * clinically significant bleeding or requiring concurrent therapeutic dose of anticoagulation
References
Publications (1)
- DERIVEDBrana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15. PMID 24928772